Navigation Links
BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
Date:11/19/2012

RALEIGH, N.C., Nov. 19, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 24th Annual Piper Jaffray Healthcare Conference.  The presentation is scheduled for Tuesday, November 27, 2012 at 11:50 a.m. Eastern Time, at The New York Palace in New York City.

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO )

Dr. Sirgo will focus on the clinical development program and the market opportunity for BEMA Buprenorphine/Naloxone (BNX) for the treatment of opioid dependence, including the New Drug Application (NDA) submission, which is anticipated to be submitted to the U.S. Food and Drug Administration (FDA) in late second quarter of 2013.  Additionally, Dr. Sirgo will discuss progress made by BDSI and its commercial partner, Endo Health Solutions, with the ongoing Phase 3 clinical studies for BEMA Buprenorphine for the treatment of chronic pain.

The presentation will be webcast live and can be accessed at www.bdsi.com.  For those who are not available to listen to the live broadcast, a replay of the webcast will be available on the BDSI website.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it is marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is licensed on a worldwide basis to Endo Health Solutions.  Additionally, BDSI is developing a high dose formulation of buprenorphine in combination with naloxone (BNX) for the treatment of opioid dependence.  Both BEMA Buprenorphine and BNX are in Phase 3 clinical development.  BDSI's headquarters is located in Raleigh, North Carolina.  For more information visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL™ is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, the results of the Company's 2012 and 2013 initiatives and potential milestones described herein) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
2. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
3. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
4. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
5. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
6. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
7. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
8. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
9. PIMCO founder Bill Gross and wife, Sue, make transformational gift to Cedars-Sinais Advanced Health Sciences Pavilion
10. Alimera Sciences Names European Management Team
11. Amarantus BioSciences Appoints Dr. Robert J. Zimmerman as Product Development Advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ... their offering. ... for drug delivery technologies will rise from USD 20 Billion in ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding ...
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... , ... More than half of Americans suffering from noise-induced hearing loss do ... that causes hearing loss? May 1 marks the beginning of Better Hearing & Speech ... well as schedule a hearing evaluation for anyone with concerns about his/her hearing. , ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... (The National Campaign) announces its support for the Access to Contraception for Women ... Shaheen (D-NH) and Rep. Jackie Speier (D-CA), will help to ensure that all ...
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading provider of ... which enables sleep physicians to create and edit their interpretation reports. This solution ... a familiar interface that does not require additional training to use. It also ...
(Date:4/28/2017)... ... ... affects much more than energy – it also has mental and physical benefits. According to ... time, which can increase the risk of having a car accident. , This week ... to help you sleep better and feel better:, , Turn off ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces ... an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start ... 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and maintenance ...
Breaking Medicine News(10 mins):